Revised: 15 January 2026
Safety Information
Dear Healthcare Professional Letters
This section provides copies of letters sent to healthcare professionals by the therapeutic products industry. These letters detail possible safety or quality concerns, they are published here on behalf of the industry. These letters are provided voluntarily and this section may not be comprehensive.
| Date sent | Product | Reason |
|---|---|---|
| 20 November 2025 | Codeine Phosphate Tablets (Noumed) (PDF, 2 pages, 594 KB) | Codeine Phosphate Tablets (Noumed) 15 mg, 30 mg and 60 mg - Overlabelling of cartons and blister packs due to stock shortages / out of stock |
| 22 October 2025 | Estradot (PDF, 3 pages, 451 KB) | Recent complaints for Estradot® transdermal patches (25, 50, 75 and 100 mcg/24 hrs) |
| 13 October 2025 | Paxlovid (PDF, 5 pages, 322 KB) | Paxlovid (nirmatrelvir/ritonavir) treatment in patients with severe renal impairment |
| 24 September 2025 | Risperdal (PDF, 3 pages, 213 KB) | Discontinuation of RISPERDAL® (risperidone) tablets across all strengths as of 15 December 2025 |
| 22 September 2025 | Ribomustin (PDF, 2 pages, 216 KB) | Discontinuation of RIBOMUSTIN® (bendamustine hydrochloride) 25mg & 100mg powder for infusion as of 30 November 2025 |
| 17 September 2025 | Epilim (PDF, 2 pages, 167 KB) | Updated safety information for valproate: Risk in pregnancy and women of childbearing potential - lower birth weight following in utero exposure to valproate |
| 15 September 2025 | Lenalidomide Viatris (PDF, 2 pages, 379 KB) | Lenalidomide Viatris (lenalidomide) Capsules - NZ-specific cartons |
| 12 September 2025 | Polivy (PDF, 3 pages, 169 KB) | Infusion site extravasation is a new identified risk for Polivy (polatuzumab vedotin) |
| 8 September 2025 | Tegretol (PDF, 1 page, 156 KB) | Tegretol (carbamazepine) liquid: limitation of use in neonates |
| 22 August 2025 | Topiramate Actavis (PDF, 7 pages, 848 KB) | Topiramate: New restrictions to prevent exposure during pregnancy |
| 14 August 2025 | Vancomycin (as hydrochloride) (PDF, 1 page, 114 KB) | Vancomycin (as hydrochloride) approval for European batch to mitigate short-term gap in supply |
| 12 August 2025 | Lenalidomide Viatris (PDF, 2 pages, 306 KB) | Lenalidomide Viatris (lenalidomide) capsules – alternative registered foils |
| 4 August 2025 | Ocrevus (PDF, 3 pages, 219 KB) | Ocrevus (ocrelizumab): liver injury (without findings of viral hepatitis) |
| 21 July 2025 | CellCept (mycophenolate mofetil) (PDF, 3 pages, 135 KB) | New important identified risk: anaphylactic reaction |
| 14 July 2025 | Lenalidomide Viatris (PDF, 2 pages, 543 KB) | Lenalidomide Viatris capsules (lenalidomide): labelling exemption for alternative registered foils |
| 26 June 2025 | Risperdal (PDF, 8 pages, 308 KB) | Accidental overdoses in children and adolescents treated with risperidone 1mg/ml oral solution following administration errors |
| 30 May 2025 | Ventolin (PDF, 2 pages, 200 KB) | Ventolin (salbutamol (as sulfate) aerosol inhaler) - reinforcing information regarding number of prescribed doses available |
| 22 May 2025 | Estradiol (Mylan) (PDF, 3 pages, 352 KB) | Estradiol Transdermal Patches (Mylan) granted full consent; US packs will continue to be supplied in the short-term |
| 22 May 2025 | Zyprexa IM (PDF, 2 pages, 226 KB | Zyprexa IM (olanzapine) 10mg powder for injection: Temporary supply of overseas product |
| 7 April 2025 | Topamax (PDF, 4 pages, 143KB) | Topamax (topiramate): New restrictions to prevent exposure during pregnancy |
| 31 March 2025 | Venofer (PDF, 2 pages, 314KB) | Important information: VENOFER® (iron sucrose) 20 mg/mL solution for injection INTERIM PACKAGING |
| 18 March 2025 | GONAL-f (PDF, 1 page, 164 KB) | Editorial changes to the printed volumes on GONAL-f Pen labels. |
| 12 February 2025 | Konakion MM Paediatric (PDF, 2 pages, 284 KB) | KONAKION MM Paediatric 2mg/0.2mL solution for injection: Temporary supply of overseas product |
| 28 January 2025 | Imbruvica (PDF, 4 pages, 296 KB) | Newly identified risk of hepatotoxicity (including hepatic failure) in warnings and precautions section of the Imbruvica NZ data sheet and consumer medicine information |
